- Hong Kong
- /
- Specialty Stores
- /
- SEHK:1255
TATA Health International Holdings First Half 2023 Earnings: HK$0.051 loss per share (vs HK$0.083 profit in 1H 2022)
TATA Health International Holdings (HKG:1255) First Half 2023 Results
Key Financial Results
- Revenue: HK$104.1m (up 64% from 1H 2022).
- Net loss: HK$12.3m (down by 161% from HK$20.2m profit in 1H 2022).
- HK$0.051 loss per share (down from HK$0.083 profit in 1H 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
TATA Health International Holdings shares are down 2.4% from a week ago.
Risk Analysis
We should say that we've discovered 2 warning signs for TATA Health International Holdings that you should be aware of before investing here.
Valuation is complex, but we're here to simplify it.
Discover if TATA Health International Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:1255
TATA Health International Holdings
An investment holding company, engages in the trading of footwear and healthcare products, and provision of financial services and online medical services in Hong Kong, Australia, Macau, and Mainland China.
Overvalued with worrying balance sheet.